|D001327||Autoimmune Diseases NIH||0.38|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 that are not hospitalized at the time of enrollment.
Description: Confirmed symptom resolution over a continuous period ≥ 48 hours, defined as PGI-Severity of 'Normal' in Participants whose Baseline PGI-Severity value was 'Mild'; or, a PGI-Severity of 'Normal' or 'Mild' in participants whose Baseline PGI-Severity value was 'Moderate' or 'Severe'.Measure: Time to substantial alleviation of COVID-19 symptoms Time: Up to 28 days.
Description: Hospitalization will be determined by Investigator's clinical judgement. Where applicable, Investigators should follow local recommendations for hospitalization of patients with COVID-19 within their institution.Measure: The proportion of participants who require COVID-19 related hospitalization, are hospitalized for COVID-19 related medical support, or are deceased within 28-days following randomization. Time: Up to 28 days.
Description: Days from baseline participant remains alive.Measure: Number of alive hospital free days at Day 28. Time: 28 days
Description: Cycle Thresholds assessed by RT-qPCR.Measure: Mean change from Baseline to Day 14, Day 21, and Day 28 in SARS-CoV-2 viral load. Time: Up to 28 days
Description: Oxygen saturation will be obtained after the participant has been resting for 5 minutes.Measure: Change from Baseline to Day 8, Day 14, Day 21, and 28 in the slope of oxygen saturation levels (SpO2) assessed per protocol. Time: up to 28 days
Description: Measured by changes in participant rated Clinical Global Impression.Measure: Clinical Global Impression (CGI) Severity and Change measures from Baseline to Day 8, Day 14, Day 21, and 28. Time: Up to 28 days
Description: Measured by changes in participant rated Patient Global Impression.Measure: Patient Global Impression (PGI) Severity and Change measures from Baseline to Day 8, Day 14, Day 21, and 28. Time: Up to 28 days
Description: Summary measure integrating semi-daily serial assessments of a subject's symptom count and severity over the duration of the study.Measure: Change in the area under the curve for Net Symptom Burden from Baseline to Day 8, Day 14, Day 21, and 28. Time: Up to 28 days
Description: Assessed by the Clinical Status Ordinal Scale established in the remdesivir ACTT study. Scale is 1-8, with 1 being the least severe and 8 being the most severe (death).Measure: Change in clinical status from Baseline to Day 8, Day 14, Day 21, and Day 28. Time: Up to 28 days
Description: Rate of deceased participants at day 28.Measure: All-cause mortality rate at Day 28. Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports